Unlock full details of this profile with our free Lite plan!
Sign Up and Get Free AccessMainstay Medical - About the company
Mainstay Medical is a public company based in Dublin (Ireland), founded in 2008. It operates as a Provider of rehabilitation solutions for patients and doctors. Mainstay Medical has raised $27.2M in funding from Fountain Healthcare Partners and Sofinnova Partners. The company has 143 active competitors, including 29 funded and 8 that have exited. Its top competitors include companies like Theranica, MedRhythms and FIRE1.
Company Details
Provider of rehabilitation solutions for patients and doctors. The company has developed "ReActiv8" a neurostimulation therapy device for chronic low back pain. Physicians provide the device for patients to monitor muscle dysfunction and patient outcomes in pain management.
- Website
- mainstaymedical.com
- Email ID
- *****@mainstay-medical.com
- Phone Number
- +1 **********
- Registered Address
- Clonmel House, Forster Way 0 K67F2K3 Swords, Co. Dublin
Key Metrics
Founded Year
2008
Location
Dublin, Ireland
Stage
Public
Total Funding
$27.2M in 8 rounds
Latest Funding Round
Investors
Ranked
3rd among 143 active competitors
Exit Details
Public
Legal entities associated with Mainstay Medical
Mainstay Medical is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Jan 30, 2018 | - | - | - |
Get your free copy of Mainstay Medical's company profile
Mainstay Medical's funding and investors
Filter this listMainstay Medical has raised a total funding of $27.2M over 8 rounds. Its first funding round was on Jul 2010. Its latest funding round was a Post IPO round on Feb 26, 2024 for $125M. 6 investors participated in its latest round, which includes Gilde Healthcare, Perceptive Advisors, Capricorn Partners and IPF Partners.
Mainstay Medical has 13 institutional investors including Fountain Healthcare Partners, Sofinnova Partners and Gilde Healthcare.
Here is the list of recent funding rounds of Mainstay Medical:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Feb 26, 2024 | $125M | Post IPO | 9105374 | 5255120 | |
Feb 11, 2021 | $108M | Post IPO | 9125487 | 7294683 | |
Feb 15, 2018 | $37.2M | Post IPO | 9064995 | 7520958 |
Access funding benchmarks and valuations. Sign up today!View details of Mainstay Medical's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Mainstay Medical's Competitors and alternates
Top competitors of Mainstay Medical include Theranica, MedRhythms and FIRE1. Here is the list of Top 10 competitors of Mainstay Medical, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Theranica 2016, Bridgewater (United States), Series C | Developer of therapeutic devices for pain management | $86M | 65/100 | |
2nd | MedRhythms 2013, Boston (United States), Series B | Provider of wearable devices to combat neurological injuries and recover walking functions | $60M | 57/100 | |
3rd | Mainstay Medical 2008, Dublin (Ireland), Public | Provider of rehabilitation solutions for patients and doctors | $27.2M | 54/100 | |
4th | Developer of non-invasive remote monitoring devices for managing chronic diseases | $202M | 52/100 | ||
5th | NeuroLutions 2007, St. Louis (United States), Series A | Developer of robotic glove controlled by brain | $28.3M | 50/100 | |
6th | ZetrOZ 2009, Trumbull (United States), Series A | Wearable bioelectronic products | $6.78M | 50/100 | |
7th | Non-invasive pain-monitoring device | $26M | 49/100 | ||
8th | nyra health 2020, Vienna (Austria), Seed | Digital therapy platform providing individualized treatment plans | $4.92M | 45/100 | |
9th | Open collaborative platform for detection of neurocognitive problems | $962K | 44/100 | ||
10th | Profusa 2009, San Francisco (United States), Series C | Biochemical sensors for chronic disease management | $62.2M | 42/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Mainstay Medical's competitors? Click here to see the top ones
Mainstay Medical's Investments and acquisitions
Mainstay Medical has made no investments or acquisitions yet.
Reports related to Mainstay Medical
Here is the latest report on Mainstay Medical's sector:
News related to Mainstay Medical
Filter this listMedia has covered Mainstay Medical for a total of 5 events in the last 1 year, 4 of them have been about company updates.
•
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue ShieldBusiness Wire•Apr 28, 2025•Mainstay Medical
•
Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®Business Wire•Jan 16, 2025•Mainstay Medical
•
Mainstay Medical Announces Positive Results from RESTORE Clinical Trial Evaluating ReActiv8®Business Wire•Jan 16, 2025•Mainstay Medical
•
Mainstay Medical Announces New ICD-10 Diagnosis Code for Multifidus DysfunctionBusiness Wire•Oct 03, 2024•Mainstay Medical
•
Mainstay Medical announces that you have received approvals for MRI labeling regarding the Reactiv8® Restorative Neurostimulation SystemtmBusiness Wire•Jul 10, 2024•Mainstay Medical
•
Mainstay Medical Announces Publication of First Neuromodulation Study for Low Back Pain with 5-Year Follow-upBusiness Wire•Mar 19, 2024•Mainstay Medical
•
Mainstay Medical announces the publication of clinical results for the comparison of older and younger patientsBusiness Wire•Mar 12, 2024•Mainstay Medical
•
Mainstay Medical Announces US$125M Equity Financing TransactionFinSMEs•Feb 27, 2024•Mainstay Medical, Gilde Healthcare, Viking Global Investors, Ally Bridge Group and 4 others
•
Mainstay Medical Announces FDA Approval for MRI Labeling of ReActiv8® Restorative Neurostimulation System TMBusiness Wire•Feb 13, 2024•Mainstay Medical
•
Mainstay Medical announces the preservation of the FDA approval for the MRI identification of the Reactiv8® Restorative neurostimulation system TMBusiness Wire•Feb 13, 2024•Mainstay Medical
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Mainstay Medical
Explore our recently published companies
- Axial Adventure - Mission Viejo based, 2022 founded, Unfunded company
- Market Minds Asdvisory - London based, 2012 founded, Unfunded company
- Ark.today - 2015 founded, Unfunded company
- GlobalAssist - Dubai based, 2024 founded, Unfunded company
- Khajuraho Dairy Products - India based, Unfunded company
- Verbeeminstallaties.nl - Netherlands based, Unfunded company